News Focus
News Focus
Followers 15
Posts 904
Boards Moderated 0
Alias Born 02/07/2020

Re: Investor082 post# 754295

Saturday, 03/15/2025 5:08:07 PM

Saturday, March 15, 2025 5:08:07 PM

Post# of 824132
Yet, Delve Insight has DCVax as the #1 treatment for GBM through 2030. (https://www.delveinsight.com/report-store/dcvax-l-emerging-drug-insight-and-market-forecast). Go figure.

Your comment that other approvals will take excessive time seems off the mark. Pharmaceutical companies with approved drugs may receive conditional approvals and accelerated pathways for other indications and combination therapies. Additional confirmatory trials typically do not involve reinventing the wheel.

Lastly, I'm curious about your knowledge of NorthWest's financial relationships with "big pharma". I'm guessing you're guessing. Here's what I do know:
Despite all the negativity posted 24/7 on this board, Northwest has a very loyal longstanding shareholder base, that seems to understand the science and broad potential of the DCVax platform. I doubt that will decline with the MHRA's upcoming approval decision.

You guys have been very busy lately.
_________________________
Be prepared for another lost decade...The problem is they don’t have a big pharma partner who is willing to...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News